Efficacy analysis and prediction in phase II clinical trials of non-small cell Lung Cancer
This thesis is submitted in partial fulfillment of the requirements for the degree of Bachelor of Pharmacy, 2023.
Κύριος συγγραφέας: | Hoque, Ismoth Ara |
---|---|
Άλλοι συγγραφείς: | Azam, Faruque |
Μορφή: | Thesis |
Γλώσσα: | English |
Έκδοση: |
Brac University
2024
|
Θέματα: | |
Διαθέσιμο Online: | http://hdl.handle.net/10361/23164 |
Παρόμοια τεκμήρια
-
Effect of performance status on efficacy endpoints in phase II trials of non-small cell lung cancer
ανά: Paul, Pulock
Έκδοση: (2024) -
Impact of treatment size and therapy type in phase II clinical trials of non-small cell lung cancer
ανά: Rahman, Tasnim
Έκδοση: (2024) -
Pooled analysis of response rate and overall survival of Tyrosine Kinase inhibitor combinations in phase II clinical trials of non-small cell lung cancer
ανά: Karim, Samia Binte
Έκδοση: (2024) -
Efficacy analysis of tyrosine kinase inhibitor combinations in phase II clinical trials of non-small cell lung cancer
ανά: Flora, Sanzida Alam
Έκδοση: (2024) -
Molecules associated with the development of lung cancer
ανά: Rahman, Adree, κ.ά.
Έκδοση: (2023)